Search Results

Idelalisib 100 mg  | Purity Not Available

TargetMol

Idelalisib is a small molecule inhibitor of the PI3K catalytic subunit p110δ (IC50: 2.5 nM). The selectivity for p110δ is 40- to 300-fold than p110α/β/γ.

More Information Supplier Page

Nintedanib 200 mg  | 99.36%

TargetMol

Nintedanib is an inhibitor of the receptor tyrosine kinases VEGFR/FGFR/PDGFR (IC50s: 13-34/37-610/59/65 nM for VEGFR1-3, FGFR1-4, and PDGFRα/β, respectively).

More Information Supplier Page

Nintedanib 10 mg  | 99.36%

TargetMol

Nintedanib is an inhibitor of the receptor tyrosine kinases VEGFR/FGFR/PDGFR (IC50s: 13-34/37-610/59/65 nM for VEGFR1-3, FGFR1-4, and PDGFRα/β, respectively).

More Information Supplier Page

Nintedanib 100 mg  | 99.36%

TargetMol

Nintedanib is an inhibitor of the receptor tyrosine kinases VEGFR/FGFR/PDGFR (IC50s: 13-34/37-610/59/65 nM for VEGFR1-3, FGFR1-4, and PDGFRα/β, respectively).

More Information Supplier Page

Celecoxib 200 mg  | 99.77%

TargetMol

Celecoxib is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of celecoxib is as a Cyclooxygenase Inhibitor.

More Information Supplier Page

Celecoxib 100 mg  | 99.77%

TargetMol

Celecoxib is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of celecoxib is as a Cyclooxygenase Inhibitor.

More Information Supplier Page

Nintedanib 50 mg  | 99.36%

TargetMol

Nintedanib is an inhibitor of the receptor tyrosine kinases VEGFR/FGFR/PDGFR (IC50s: 13-34/37-610/59/65 nM for VEGFR1-3, FGFR1-4, and PDGFRα/β, respectively).

More Information Supplier Page